Prior to her appointment as president and CEO, Ms Popovits served as president and COO since joining Genomic Health in February 2002, and as a director since March 2002. Previously, she served in various roles at Genentech, most recently as senior vice president of marketing and sales.
Mr Cole joined Genomic Health in 2004 as executive vice president and CFO and was named executive vice president of operations and CFO in January 2008. Previously, Mr Cole served in various senior management positions at Guidant and Applied Biosystems.
Randy Scott, chairman of Genomic Health, said: “Kim’s appointment as CEO reflects her unique experience and passion to lead all aspects of our business, as I turn my focus to the longer-term strategy and vision of the organization. This transition marks an important milestone for the company, reflecting our leadership and success in delivering personalized medicine to patients.
“Brad’s increasing responsibility as COO recognizes his contribution to the operations of the company and further strengthens our ability to deliver our services to physicians and patients around the world. I look forward to working with Kim, Brad and our entire management team as we continue our efforts to expand worldwide commercialization of the Oncotype DX breast cancer assay, advance our R&D pipeline, and move the organization toward profitability.”